Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
J1G-MC-LAKI: Remternetug in Early Alzheimer's Disease
2024-515656-20-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Remternetug with Placebo (2 arms). Primary endpoint: Time to Clinically Meaningful Progression as Measured by Clinical Dementia Rating (CDR). Planned start Mar 2025; status: authorised.
02
Drugs
remternetug
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2024-515656-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515656-20-00.